Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) said it has signed a non-binding letter of intent with a Latin American specialty distribution company to expand its commercial reach in the region.
The potential partnership aims to distribute and commercialize Voyageur’s radiology contrast media products in Mexico and other Latin American countries where Canadian regulatory approvals are recognized.
The unnamed distributor, described as an established pharmaceutical company with a strong regional presence, will oversee marketing, sales, and regulatory activities once a binding agreement is finalized, Voyageur said.
The deal is expected to be completed within 90 days.
“This agreement marks a significant step forward in our commercialization roadmap,” said Brent Willis, CEO of Voyageur. “Latin America is a critical market in our expansion plan, and this partnership lays the groundwork for long term growth.”
The agreement is a key milestone in the company’s international growth strategy, targeting underserved markets with growing demand for cost-effective imaging solutions, the company added.
Sales of Voyageur’s barium sulfate contrast media products in Latin America will be subject to local regulatory approvals, with the distributor expected to take the lead on filings, supported by Voyageur’s technical and regulatory teams.